Molecule target therapies in advanced gastric cancer

Gastric cancer is the third leading cause of cancer death worldwide and the majority of patients are diagnosed with stage III or IV. Recently many researchers discover that somatic genomic aberrations exist in gastric cancer; however, despite there are many advances in genomics of gastric cancer, there is no evidently improvement in patients' outcomes. Prognosis remains poor with a median overall survival of 12 months for patients with advanced gastric cancer. The improved survival with trastuzumab, ramucirumab and apatinib displayed the promise and importance of molecular targeted therapies in gastric cancer. Here we review the current study status and ongoing clinical trials of molecule target drugs of gastric cancer briefly. Keywords advanced gastric cancer; target therapy; clinical trial